Technology Appraisal Virtual Committee Meeting

Committee A

Zoom

### Minutes: Confirmed

### Date and Time: Tuesday 10 November 2020

### Committee Members Present:

* Dr Jane Adam (Chair) Present for all notes
* Dr Brian Shine (Vice Chair) Present for all notes
* Professor Steve O’Brien (TAC C Chair) Present for notes 17 to 25
* Dr Peter Baker Present for all notes
* Mr Richard Ballerand Present for all notes
* Dr Andrew Champion Present for all notes
* Mr Mark Chapman Present for all notes
* Dr Steve Edwards Present for notes 9 to 25
* Dr Rita Faria Present for all notes
* Dr Bernard Khoo Present for all notes
* Professor G.J. Melendez-Torres Present for notes 1 to 8 & 17 to 25
* Mrs Becky Pennington Present for all notes
* Ms Pamela Rees Present for all notes
* Dr Mohit Sharma Present for all notes
* Mr Stephen Sharp Present for all notes
* Dr Alice Turner Present for notes 1 to 8 & 17 to 25
* Dr Min Ven Teo Present for notes 1 to 16
* Dr Roger Whittaker Present for all notes

### NICE Staff In attendance:

* Ross Dent, Associate Director, NICE, Present for notes 17 to 25
* Janet Robertson, Associate Director, NICE, Present for notes 1 to 16
* Thomas Feist, Project Manager, NICE, Present for all notes 9 to 16
* Louise Jafferally, Project Manager, NICE, Present for notes 1 to 8 & 17 to 25
* Emily Eaton-Turner, Technical Adviser, NICE, Present for notes 1 to 8
* Nicola Hay, Technical Adviser, NICE, Present for notes 17 to 25
* Rufaro Kausi, Technical Adviser, NICE, Present for notes 9 to 16
* Albany Meikle, Technical Analyst, NICE, Present for notes 1 to 8
* Zain Hussain, Technical Analyst, NICE, Present for notes 9 to 16
* Thomas Paling, Technical Analyst, NICE, Present for notes 17 to 25
* Mira Patel, Technology Appraisals Administrator, Present for notes 1 to 8
* Sandra Aleknavice, Technology Appraisals Administrator, Present for notes 1 to 8
* Mandy Brereton Committee Operations Assistant Project Manager, Present for notes 1 to 5
* Gemma Smith, Committee Operations Coordinator, NICE, Present for all notes
* Sophie McHugh, Committee Operations Administrator, NICE Present for all notes

**ERG Representatives in attendance:**

* Mariana Bacelar, BMJ, Evidence Review Group, Present for notes 1 to 5
* Charlotta Karner, BMJ, Evidence Review Group, Present for notes 1 to 5
* G.J. Melendez-Torres, PenTAG, Evidence Review Group, Present for notes 9 to 13
* Brian O’ Toole, PenTAG, Evidence Review Group, Present for notes 9 to 13
* Yen-Fu Chen, Warwick Evidence, Evidence Review Group, Present for notes 17 to 22
* Ewen Cummins, Warwick Evidence, Evidence Review Group, Present for notes 17 to 22

**Clinical & Patient Experts in attendance:**

* Dr Shibani Nicum, Clinical Expert, Consultant Medical Oncologist, Present for notes 1 to 5
* Professor Charlie Gourley, Clinical Expert, Chair of Medical Oncology and Honorary Consultant in Medical Oncology, Present for notes 1 to 5
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 1 to 8
* Rachel Downing, Patient Expert, Head of Policy and Campaigns at Target Ovarian Cancer Present for notes 1 to 5

### Other non-public attendees present:

* Rosalee Mason, Corporate Office Coordinator, NICE, Present for all notes
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for all notes
* Adam Storrow, Business Analyst, NICE, Present for all notes
* Ria Skelton, Editor, NICE, Present for notes 1 to 8
* Ann Greenwood, Editor, NICE, Present for notes to 9 to 16
* Hayley Garnett, Editor, NICE, Present for notes 17 to 25
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 8
* Marcela Haasova, Technical Analyst, NICE, Present for notes 9 to 16
* Cara Gibbons, Assistant Technical Analyst, NICE, Present for notes 9 to 16
* Ella Livingstone, Technical adviser - commercial risk assessment, NICE, Present for notes 1 to 8
* Claire Hawksworth, Technical Analyst – Evidence Generation, NICE, Present for notes 1 to 8
* Anne Murray-Cota NICE, Health Technology Assessment Analyst, NICE, Present for notes 17 to 25
* Stevie Okoro, Technical analyst, Commercial risk NICE, Present for notes 9 to 25
* Sola Akinbolade. Evidence Synthesis/Horizon Scanning Specialist, NIHRIO, Present for notes 1 to 5 & 9 to 13

### Notes

### Appraisal of niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) and representatives from GSK.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. Dr Alice Turner declared an indirect financial interest as she has provided Consultancy work for GSK in area of COPD.
      1. It was agreed that this declaration would not prevent Alice from participating in discussions on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening to the group for discussion.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were thanked and asked to leave the meeting.

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of mepolizumab for treating severe eosinophilic asthma (review of TA431) [ID3750]

### Part 1 – Open session

1. The Vice Chair welcomed the invited Evidence Review Group (ERG) representatives and representatives from GSK.
2. The Vice Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.  
   1. Dr Alice Turner declared that she has provided consultancy work for GSK about COPD and has also recruited patients to competitor trials (Benraluzimab, AstraZeneca) in COPD.
      1. It was agreed that this was a direct conflict which prevented Alice from attending discussion on this topic
3. No further conflicts of interest were declared for this appraisal.
4. The Vice Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
5. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening to the group for discussion.

### Part 2 – Closed session (company representatives, ERG representatives and members of the public were thanked and asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of brolucizumab for treating wet age-related macular degeneration [ID1254]

### Part 1 – Open session

1. The Committee C Chair welcomed the Evidence Review Group (ERG) representatives and representatives from Novartis.
2. The Committee C Chair asked all committee members, ERG representatives and NICE staff present to declare any relevant interests.
   1. Becky Pennington declared non-financial personal interest as she has co-authored conference abstracts (published) and an HTA report (accepted but not yet published) and is working on journal manuscripts reporting a cost-effectiveness analysis of bevacizumab, aflibercept and ranibizumab in macular oedema. Funding for the research was provided by NIHR and has ended, but this work expresses the finding that bevacizumab is cost-effective.
      1. It was agreed that this declaration would not prevent Becky from participating in discussions on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Committee C Chair gave the presentation on the clinical effectiveness and cost effectiveness of the treatment.
5. The Committee C Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening to the group for discussion.

### Part 2a – Closed session (company representatives and members of the public were thanked and asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.